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Abstract Modulation of mRNA expression of choline acetyl-
transferase (ChAT) and the vesicular acetylcholine transporter 
(VAChT) by the glucocorticoid dexamethasone and by retinoic 
acid was examined in two neuronal cell lines: basal forebrain-
derived SN56 and pheochromocytoma PC12. Dexamethasone 
up-regulated ChAT and VAChT in SN56 cells, while it had 
inhibitory effects on these genes in PC12 cells. Retinoic acid 
stimulated the cholinergic markers in both cell types, but in SN56 
cells its effect was partially additive with that of dexamethasone, 
whereas it was much smaller and abrogated by dexamethasone in 
PC12 cells. Acetylcholine content correlated with these mRNA 
changes. The presence of a glucocorticoid response element 
consensus sequence in the VAChT/ChAT gene locus suggests 
direct transcriptional regulation by glucocorticoids. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Cholinergic neurotransmission is essential for many diverse 
functions of the nervous system, including the control of skel-
etal muscles, autonomic activity, the central control of move-
ment, and learning and memory. Normal functioning of chol-
inergic neurons depends upon the expression of two proteins: 
choline acetyltransferase (ChAT) which synthesizes acetylcho-
line (ACh), and the vesicular ACh transporter (VAChT) 
which transports ACh into secretory vesicles. Of those two 
cholinergic markers, ChAT has been studied more extensively, 
and most information on the regulation of the cholinergic 
phenotype is derived from studies of ChAT activity and ex-
pression. ChAT expression is regulated during development 
and in the adult nervous system by several trophic factors 
(the best characterized being nerve growth factor), as well as 
by neurotransmitters, vitamins and hormones, including thy-
roid hormones [1-3], estradiol [4] and glucocorticoids [5]. 
Hormones belonging to the latter class are of particular inter-
est because they are important for brain development as well 
as in behavioral responses to stress. Experiments in vivo or in 
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primary cultures of brain neurons indicate that the regulation 
of the cholinergic phenotype by steroids is complex, involving 
both regulation of neuronal maturation [6,7], as well as mod-
ulation of ChAT itself. In most in vivo systems, exposure to 
glucocorticoids reduces ChAT activity [5,8,9]. However, other 
studies indicate that the response strongly depends on the 
administered dose, the stage of brain development and the 
brain region [10,11]. It has been reported that treatment 
with glucocorticoids significantly reduces ChAT activity and 
ACh content in cultured rat pheochromocytoma PC 12 cells, 
which are derived from rat adrenal medulla and exhibit many 
properties of sympathetic neurons [12]. The non-neuronal pro-
duction and release of ACh by pituitary cells, on the other 
hand, appears to be slightly up-regulated by glucocorticoids 
[13]. 
In contrast to ChAT, little is know about the regulation of 
VAChT expression. However, recent studies have shown that 
the region of the mammalian genome encoding ChAT and 
VAChT exhibits an unusual organization: the intronless 
VAChT open reading frame is entirely contained within the 
first intron of the ChAT gene [14,15]. Differential promoter 
use and alternative splicing result in a complex pattern of 
expression of this 'cholinergic locus' leading to the formation 
of many mRNA species that differ in the 5' end and contain 
either the ChAT or VAChT coding region. The 5'-most exon 
is shared by some ChAT and VAChT mRNAs, but the most 
abundant classes of transcripts are initiated at separate 
ChAT- and VAChT-specific promoters. This genomic organ-
ization suggests that some regulatory elements could be 
shared between the two genes; however, the mechanisms reg-
ulating ChAT transcription are only partially understood (re-
viewed by Wu and Hersh [16]), and the regulation of VAChT 
expression is just beginning to be explored [17-19]. 
As a first step to investigate the molecular mechanisms of 
ChAT/VAChT regulation by steroid hormones, we examined 
ChAT and VAChT mRNA and ACh content in two neuronal 
cell lines treated with the synthetic glucocorticoid dexametha-
sone and with retinoic acid. Here we present evidence that 
cholinergic properties of these cells are regulated by glucocor-
ticoids at the mRNA level and that the regulation by both 
glucocorticoids and retinoids is cell-type specific. 
2. Materials and methods 
2.1. Cell culture 
Mouse septal neuron X neuroblastoma hybrids SN56 cells (a gift of 
Dr. Bruce Wainer) were created by fusing N18TG2 neuroblastoma 
cells with murine (strain C57BL/6) neurons from postnatal day 21 
septa [20,21]. SN56 cells were maintained in Dulbecco's modified Ea-
gle medium (DMEM) containing 10% fetal bovine serum (FBS) and 
50 u.g/ml gentamicin. Rat pheochromocytoma PC12 cells were grown 
in DMEM containing 5% FBS, 10% horse serum, and 50 ug/ml gen-
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tamicin. When the cells were grown in the presence of test com-
pounds, i.e. glucocorticoids or retinoids, the medium was changed 
every 24 h. 
2.2. Northern analysis 
2.2.1. Extraction of RNA. Total RNA was extracted from SN56 
cells using the acid guanidinium isothiocyanate (GT)-phenol-chloro-
form method [22,23]. Prior to lysis, cells were washed twice with 
phosphate-buffered saline and then dissolved in 4 M GT solution. 
Following lysis and phenol/chloroform extraction, RNA was precipi-
tated with isopropanol, and the pellet was washed with 70% ethanol, 
dissolved in RNase-free water and stored at —80°C. 
2.2.2. Northern blotting. RNA samples equalized for ribosomal 
RNA content (20 ug/lane) were size-fractionated on a 1% agarose 
gel containing 6% formaldehyde and transferred to a Hybond-N+ 
nylon membrane (Amersham). Hybridization was carried out in the 
Rapid-hyb solution (Amersham), according to manufacturer's instruc-
tions. DNA probes were labeled with [a-32P]dCTP (New England 
Nuclear) to a specific activity of 1-2X 109 cpm/u.g DNA using Redi-
prime labeling kit (Amersham). Final washes were in 0.2 X saline-so-
dium citrate (SSC), 0.1% sodium dodecyl sulfate (SDS) at 60°C for 
ChAT and at 65°C for VAChT. The blots were visualized and band 
intensities were quantified with a Phosphorlmager 400E using Image-
Quant NT software (Molecular Dynamics). 
2.2.3. Probes. For the ChAT probe, we used a 1.32-kb cDNA 
fragment amplified by PCR from mouse brain cDNA (Clontech) 
with the following oligonucleotide primers: 
Forward: 5'-CGGGATCCTGCCTCATCTCTGGTGT-3' 
Reverse: 5'-ACGGGTCCATAACAGCAGAACA-3' 
A 0.8-kb mouse VAChT cDNA probe located within the VAChT 
coding sequence was described previously [18]. 
2.3. Extraction and measurement of ACh 
Cells were grown to subconfluence in 35-mm culture dishes. After 
the desired treatment, the medium was removed and the cells were 
incubated for 1 h at 37°C in a physiological salt solution (pH 7.4) 
supplemented with 5 u,M choline and 15 uM neostigmine and consist-
ing of the following (in mM): NaCl, 135; KC1, 5; CaCl2, 1; MgCl2, 
0.75; glucose, 10; HEPES, 10. The cells were washed once with ice-
cold, choline-free physiological salt solution supplemented with 15 
u,M neostigmine, methanol was added, the cells were scraped into 
the methanol, and the suspension was transferred to a polypropylene 
tube. A solution of 15% 1 M formic acid and 85%o acetone was added, 
the tubes were vortexed, and the extracts centrifuged to precipitate the 
protein. Both the protein pellets and the supernatant fluids, containing 
ACh, were dried under a vacuum. The ACh pellet was resuspended in 
HPLC mobile phase (28 mM sodium phosphate, pH 8.5, supple-
mented with Kathon CG Reagent), sonicated, and filtered (0.2 (xm 
Nylon-66, Rainin Instrument). The content of ACh was determined 
by HPLC with an enzymatic reactor containing acetylcholinesterase 
and choline oxidase and an electrochemical detector using a commer-
cial kit (Bioanalytical Systems) based on the method of Potter et al. 
[24]. Protein was determined by the method of Smith et al. [25]. 
3. Results and discussion 
We measured the effect of a glucocorticoid receptor agonist, 
dexamethasone, on intracellular ACh levels and ChAT and 
VAChT m R N A in two neuronal cell lines: rat pheochromo-
cytoma PC12 cells and the mouse septal cell line SN56. Con-
sistent with a previous report [12], a 2-day treatment with 
1 u M dexamethasone reduced ACh content in P C 12 cells by 
50% (Fig. 1A). All-fraws-retinoic acid (t-RA, 1 uM) caused 
only a moderate (24%) increase in ACh content in these cells. 
This effect of t -RA was completely abrogated by dexametha-
sone, as shown by the combined treatment. In contrast, in 
septal SN56 cells, dexamethasone treatment nearly doubled 
intracellular A C h content (Fig. IB). In agreement with our 
previous findings [26], t -RA tripled intracellular ACh concen-
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Fig. 1. Differential effects of dexamethasone on ACh content in (A) 
PC12 and (B) SN56 cells. Cells were treated for 48 h in the presence 
or absence of 1 U.M retinoic acid, 1 U.M dexamethasone, or both. 
Intracellular ACh was measured in cell extracts as described in Sec-
tion 2. The results are presented as means ± SD. All comparisons 
between groups were statistically significant (P<0.05; Tukey test) 
except for the two groups indicated by *. 
tration in these cells. Fur thermore, the effect of dexametha-
sone in SN56 cells was partially additive with that of t-RA. 
Dexamethasone increased the ACh content of SN56 cells in a 
time- and concentration-dependent, saturable fashion (Fig. 2). 
The maximal effect of dexamethasone was observed after a 72 
h treatment and was sustained until the last time point exam-
ined, 96 h (Fig. 2A). The saturating concentration of the 
hormone was between 10 n M and 100 n M (Fig. 2B). The 
concentration that resulted in a half-maximal effect (EC50) 
was 6 n M . 
Nor thern blotting with cholinergic locus-specific probes 
demonstrated that the dexamethasone effect occurs at the 
m R N A level in both cell types (Figs. 3 and 4). The ChAT-
and VAChT-specific probes were derived from the respective 
coding regions, and they recognize all known m R N A var-
iants; however, the size differences between the variants are 
too small to be detected under our experimental conditions, 
and therefore ChAT and VAChT transcripts appear as single 
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Fig. 2. Dexamethasone causes time- and concentration-dependent 
increases in intracellular ACh levels in SN56 cells. (A) SN56 cells 
were treated for the time periods indicated in the presence of 1 uM 
dexamethasone. ACh was measured in cell extracts as described in 
Section 2. (B) Cells were grown for 72 h in the presence of various 
concentrations of dexamethasone and ACh was measured as in (A). 
bands. Analysis of band intensities from Northern blots 
showed that, in PC12 cells, dexamethasone reduced ChAT 
and VAChT mRNA levels by 50% and t-RA increased them 
by 30^10%. In dexamethasone-treated PC 12 cells, t-RA had 
almost no effect on ChAT and VAChT mRNA (Fig. 3). In 
SN56 cells, the ChAT and VAChT mRNA levels were in-
creased by dexamethasone by 80%, and 120%, respectively 
(Fig. 4). The effect of dexamethasone on ChAT/VAChT 
mRNA was additive with that of t-RA. These data are in 
agreement with the effects of these compounds on ACh con-
tent in both cell lines. The observation that, in both cell lines, 
the regulation of VAChT mRNA expression by dexametha-
sone parallels that of ChAT mRNA further supports previous 
findings that both genes are coordinately up-regulated by var-
ious extracellular stimuli [17-19]. The result of the glucocorti-
coid treatment of PC 12 cells, however, provides the first dem-
onstration of a coordinated reduction in mRNA levels of both 
genes. 
Taken together, the data demonstrate that the regulation of 
expression of the cholinergic locus by dexamethasone and 
t-RA differs in SN56 and PC12 cells. Dexamethasone has 
opposite effects on ChAT/VAChT expression and ACh pro-
duction in SN56 cells (up-regulation) and in PC 12 cells 
(down-regulation). Retinoic acid has only a moderate effect 
on those markers in PC 12 cells, and a substantial effect in 
SN56 cells. The molecular basis of these differences remains 
to be investigated. We have shown previously that the regu-
lation of the cholinergic properties of SN56 cells by retinoids 
is mediated by the alpha subtype of the retinoic acid receptor 
(RARrx) [18,26]. The simplest interpretation of the retinoic 
acid treatment data presented here is that the regulation of 
the cholinergic locus in PC 12 cells also involves RARa, and 
the difference in the magnitude of the effect results from dif-
ferent availability of that receptor, or its co-activator, in the 
two cell lines. Steroid hormones also exert their biological 
actions by interacting with nuclear receptors which are tran-
scription factors. The glucocorticoid receptor (GR) homo-
dimer binds to the glucocorticoid response elements (GRE) 
in the promoters of responsive genes. Recently, Cervini et 
al. [27] cloned and sequenced the 5' non-coding region of 
the rat VAChT gene and localized two VAChT-specific pro-
moters, each comprising several transcription start sites. In 
that region there is a half-site of the consensus GRE present 
at 868 bp upstream from the VAChT translation initiation 
codon. It is not known whether this element is biologically 
active, and whether it can regulate both ChAT and VAChT 
transcription. In addition to their direct actions as transcrip-
tion factors, both RAR and GR can participate in complex 
cross-talk between different regulatory pathways. For exam-
ple, it has been shown that both RAR and GR interact 
strongly with the proteins (e.g. CBP/p300), that are required 
for activation of both CREB and AP-1 [28,29]. Additionally, 
GR has been shown to modulate gene expression by interfer-
ing with N F - K B signaling pathways [30,31], modulation of the 
expression of transcription factors including RAR [32] and the 
proteins of the C/EBP family [33], and direct binding to tran-
scription factors (e.g. API, N F - K B ) [34]. There are indeed 
indications that AP-1- and NF-KB-mediated transcription 
may contribute to the regulation of ChAT/VAChT by gluco-
corticoids. In vivo experiments involving both adrenalectomy 
and administration of dexamethasone showed that glucocorti-
coids interfere with both API and N F - K B binding activity in 
rat brain [35,36]. There are putative API and N F - K B sites in 
the promoter regions of both rodent and human cholinergic 
gene locus. It was shown in reporter gene assays that while 
dexamethasone did not enhance basal transcription from the 
human proximal ChAT promoter, it had an agonistic effect on 
Jun/Fos-induced promoter activity [37]. This effect, however, 
may strongly depend on the cell type, since nuclear receptors 
and AP-1 can act either synergistically or antagonistically de-
pending on conformation and availability of specific protein 
components of the DNA binding complex [38]. On the other 
hand, Gotoh et al. [33] showed recently that glucocorticoid 
induction of the rat arginase gene is mediated through the 
transcription factor C/EBPp, which binds to a cluster of re-
sponse elements in the arginase enhancer. There are four per-
fect matches of the C/EBP consensus binding site (TT/ 
GNNGNAAT/G) clustered in the murine proximal ChAT 
promoter region, and the rat distal ChAT/VAChT promoter 
also contains four perfect matches of this sequence. Thus, the 
regulation of the ChAT/VAChT locus by dexamethasone and 
retinoids may involve both direct transcriptional activation 
through their respective response elements, and modulation 
of other signal transduction pathways, with the final outcome 
dependent on the specific cellular environment. 
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Fig. 3. Effect of dexamethasone on (A) ChAT and (B) VAChT mRNA levels in PC12 cells. Cells were treated as described in Fig 1. Total 
RNA (20 |ig/lane) was transferred to a nylon membrane and probed with mouse ChAT and VAChT cDNAs. The hybridizing bands were vis-
ualized using a Phosphorlmager 400E (upper panels) and band intensities were quantified with ImageQuant software (Molecular Dynamics). 
Ethidium bromide staining of rRNA bands (middle panels) demonstrates equal loading between lanes. The graphs in the lower panels present 
means ± range of band intensities from two experiments. 
To our knowledge this is the first demonstration that the 
effects of glucocorticoids and retinoids on the mRNA of 
ChAT and VAChT are cell-type specific. If a similar cell-
type dependence occurs in vivo, it would indicate that, in 
different populations of cholinergic neurons, corticosteroids 
either up-regulate or down-regulate cholinergic function. It 
is worth noting that PC 12 cells may represent a special case 
in this regard as they are derived from adrenal chromaffin 
cells which are exposed to high concentrations of adrenal 
cortical hormones in vivo, and it is the action of these hor-
mones which maintains their adrenergic phenotype [39]. 
In in vivo studies, administration of dexamethasone to rats 
altered ChAT activity in brain in a region-specific manner. 
Notably, hippocampal ChAT activity was elevated but that 
of the hypothalamus remained unchanged [40]. In contrast, 
ChAT activity of the gastrointestinal cholinergic system was 
reduced by the administration of corticosterone [41]. In a 
recent study by Hu et al. [8], subcutaneous injection of dex-
amethasone into rat pups resulted in a dramatic decrease of 
ChAT immunoreactivity in the caudate-putamen, with no 
change in other forebrain structures including septum. These 
in vivo experiments do not clarify whether the effects of glu-
cocorticoids on cholinergic neurons are directly receptor-
mediated, or indirect through an action on other cell types. 
Our data indicate that mechanisms exists for direct differential 
ChAT and VAChT mRNA expression in cholinergic cells of 
various origin. Since glucocorticoids are released by the adre-
nal glands in response to stress, our data suggest that stress 
may have a complex pattern of effects on cholinergic function. 
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